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Background: There is a loss of lean body mass (LBM) with increasing age. A low LBM has been associated with
increased adverse effects from prescribed medications such as chemotherapy. Accurate assessment of LBM may
allow for more accurate drug prescribing. The aims of this study were to develop new prediction equations (PEs)
for LBM with anthropometric and biochemical variables from a development cohort and then validate the best
performing PEs in validation cohorts.
Methods: PEs were developed in a cohort of 188 healthy subjects and then validated in a convenience cohort of
52 healthy subjects. The best performing anthropometric PE was then compared to published anthropometric PEs
in an older (age≥ 50 years) cohort of 2287 people. Best subset regression analysis was used to derive PEs.
Correlation, Bland-Altman and Sheiner & Beal methods were used to validate and compare the PEs against dual
X-ray absorptiometry (DXA)-derived LBM.
Results: The PE which included biochemistry variables performed only marginally better than the anthropometric PE.
The anthropometric PE on average over-estimated LBM by 0.74 kg in the combined cohort. Across gender (male vs.
female), body mass index (< 22, 22- < 27, 27- < 30 and ≥30 kg/m2) and age groups (50–64, 65–79 and ≥80 years),
the maximum mean over-estimation of the anthropometric PE was 1.36 kg.
Conclusions: A new anthropometric PE has been developed that offers an alternative for clinicians when access to
DXA is limited. Further research is required to determine the clinical utility and if it will improve the safety of
medication use.
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With increasing age, there is a decline in lean body mass
(LBM) and very often an increase in adiposity [1]. The
decline in LBM may also be accompanied by a reduction
in physical function and when a pathological threshold
is reached, the person is said to have sarcopenia [2]. In
recent times, sarcopenia has been recognized as an inde-
pendent predictor of drug related adverse outcomes in
the oncology setting where muscle wasting can be com-
mon [3,4]. Drug-related adverse effects are defined as* Correspondence: solomon.yu@adelaide.edu.au
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reproduction in any medium, provided the ormedical events related to the use of medication which
may result in disability, hospital admissions or death [5].
In patients with cancer, the use of LBM might be super-
ior to body surface area (BSA) [6]. For example, in a
prospective study of colon cancer patients treated with
5-fluorouracil (5-FU), the incidence of dose limiting tox-
icity was examined with respect to conventional dosing
of 5-FU/m2 of BSA versus 5-FU/kg of LBM. LBM was a
better predictor of toxicity (p = 0.011) but not BSA [6].
Similar findings have been reported in other studies
[7,8]. In anaesthesia, propofol pharmacokinetic parame-
ters scaled linearly to LBM is also said to provide for
improved dosing in adults [9]. Therefore, accurate
measurement of LBM may have clinical application in
improving drug prescribing safety and efficacy, especially
in older people where loss of lean mass is common.This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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LBM is the reliance on relatively inaccessible or expen-
sive methods of body composition measurements. Com-
puted tomography (CT), magnetic resonance imaging
and dual absorptiometry x-ray (DXA) are used to assess
LBM but these methods may be difficult to access in clin-
ical practice (e.g. frail or rural patients) [10]. Although the
bioelectrical impedance analysis (BIA) method is portable,
it still requires the purchase of special equipment and it’s
accuracy is also dependent on many other factors such as
state of hydration, food intake and exercise [11].
Total body weight consists of fat mass and fat free
mass. Fat free mass (FFM) consists of bone, muscle, vital
organs and extracellular fluid. LBM differs from FFM in
that lipid in cellular membranes are included in LBM
but this accounts for only a small fraction of total body
weight (up to 3% in men and 5% in women) [12]. In the
literature, bone mass has at times been included in LBM
and at other times not included [4,13].
Anthropometric-based prediction equations (PEs) have
been examined as an alternative in measuring LBM in
settings where access to these accurate methods is limited.
In a very recent study of older (≥70 years) Australian men,
FFM as estimated by three PEs were compared to FFM as
estimated by DXA (FFMDXA) [14]. The three PEs were the
Heitmann, Janmahasatian and Deurenberg equations as
shown below:
Heitmann equation [15]:
Body fat kgð Þmale ¼ 0:988  BMIð Þ
þ 0:242  weightð Þ
þ 0:094  ageð Þ−30:180
Body fat kgð Þfemale ¼ 0:988  BMIð Þ
þ 0:344  weightð Þ
þ 0:094  ageð Þ−30:180:
Janmahasatian equation [12] :
FFM kgð Þfemale ¼ 9270  weightð Þ
= 8780þ 244  BMIð Þð
FFM kgð Þmale ¼ 9270  weightð Þ
= 6680þ 216  BMIð Þð
Deurenberg equation [16]:
Body fat %ð Þ ¼ 1:2  BMIð Þ
þ 0:23  Ageð Þ– 10:8  Sexð Þ−5:4
Male = 1, Female = 0
For two of the PEs (Heitmann and Deurenberg equa-
tions), FFM was calculated by subtracting fat mass from
total body mass. In defining the FFM and LBM, the au-
thors in that study proposed that FFM and LBM could
be used interchangeably. Mitchell et al. reported thatFFM as estimated by Deurenberg equation had the
smallest mean difference and overestimated FFMDXA for
overweight men but underestimated FFMDXA for all other
body mass index (BMI) subgroups [14]. The Heitmann and
Janmahasatian equations, on the other hand, overestimated
FFMDXA across various BMI categories [14].
The addition of biochemistry variables might improve
the performance of prediction equations but few studies
have examined this. Creatine Kinase (CK) is found pre-
dominantly in skeletal muscle and serum levels were as-
sociated with the lean muscle mass [17]. There has only
been one study evaluating the relationship between LBM
and plasma creatine kinase activity (CK) and a weak and
partial correlation (r < 0.262) between log CK and LBM
was reported [18]. Serum albumin has also been reported
to reflect protein reserve and lower albumin levels have
been shown to be associated with loss of lean mass [19].
Therefore, the aims of this study were to develop and
validate PEs for LBM with anthropometric and biochem-
istry variables against DXA.
Methods
The Central Northern Adelaide Health Service Ethics of
Human Research Committee approved this study. All
participants provided written informed consent.
Study cohorts
Four study cohorts were investigated in this study: a) the
Cytokine, Adiposity, Sarcopenia and Ageing (CASA) co-
hort; b) the validation cohort (VC); c) the North West
Adelaide Health Study (NWAHS) cohort and d) the Florey
Adelaide Male Ageing Study (FAMAS) cohort. CASA was
used to derive the PEs for LBM which included anthropo-
metric and biochemistry variables. The selected LBM
PEs were then validated in a second independent co-
hort, the VC (n = 52). As sarcopenia is more prevalent
in older populations, validation of the best performing PE
and other published FFM PEs (Heitmann, Janmahasatian
and Deurenberg equations) were then undertaken in the
larger population representative NWAHS and FAMAS
cohorts (n = 2287, age ≥ 50 years).
CASA
195 population representative healthy subjects (age 18 to
83 years) were recruited from the western suburbs of
Adelaide [20]. The inclusion criteria were: being aged 18
and above, able to comply with study protocol and weight
stable over the last 3 months. We excluded those with a
serious medical illness, an acute illness in the pass
3 months or in the 2 weeks following blood sampling, an
inability to stop medications for 3 days prior to blood
sampling, being in receipt of vaccinations and pregnancy.
In undertaking the analysis, data from 7 subjects were ex-
cluded due to haemolysed or insufficient blood samples.
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This was a convenience sample of 52 healthy subjects
(age 22 – 83 years) recruited through advertisement for
another study [21]. Subjects with known medical illness
including gastrointestinal disease or symptoms, signifi-
cant respiratory, renal or cardiac disease and who were
pregnant were excluded from this study.
NWAHS
This is a longitudinal study of community dwelling
adults aged eighteen years and older. The population
which is a representative biomedical cohort of predom-
inantly of mixed European descent has been described
in detail previously [22]. DXA scans were offered to
NWAHS participants who were aged ≥ 50 years at follow
up (median time = 4 years). Participants with complete
anthropometric and DXA measurements at follow up
(2004–06) aged ≥50 were included in this analysis
(n = 1575).
FAMAS
This male only cohort has also been described in detail
elsewhere [23]. The recruitment process was very similar
to that used for the NWAHS and so the men in FAMAS
were comparable with men in the same age groups from
the NWAHS study and of mixed European descent [24].
DXA measurements at baseline (2002–2005) were obtained
on 700 participants aged 50 years and over.
Measurements
Anthropometry
Height (m) was measured without shoes using a wall-
mounted SECA stadiometer to the nearest 0.1 cm.
Weight (kg) was measured wearing light clothing to the
nearest 0.1 kg (A&D FV platform scales 0.5 – 150 kg).
Body mass index (BMI, weight/height2) was calculated.
The healthy BMI for older people is said to be between
22–27 kg/m2 [25]. Caucasians with BMI > 30 kg/m2 were
classified as obese [26].
Dual Energy X-ray Absorptiometry (DXA)
DXA analysis in all cohorts measured 3 compartments
of the total body composition; fat mass, LBM and bone
mineral content. For the purpose of this study, LBM re-
fers to soft tissues and muscle mass, but excludes fat and
bone mass. CASA: A Lunar PRODIGY whole-body scan-
ner (GE Medical Systems, Madison, WI), in conjunction
with Encore 2002 software, was used to estimate LBM.
The majority of subjects underwent DXA within 2 hours
of attending the morning clinic when blood sampling
occurred. VC: A Norland densitometer XR36 (Norland
Medical Systems, Fort Atkinson, Wisconsin, USA), in con-
junction with Illuminatus 4.2.4a software, was used to esti-
mate LBM. The DXA was performed on a separate studyday but within 2 weeks of blood sampling and given that
the subjects were healthy, it is unlikely that there would
have been significant change in body composition within
that time frame. To account for differences between ma-
chines, LBM data from the VC had a correction factor
applied to convert the data to Lunar equivalent [27].
NWAHS and FAMAS: The fan-beam Lunar PRODIGY
(GE Medical Systems, Madison, WI) in conjunction
with Encore 2002 software and a pencil-beam DPX + (GE
Medical Systems, Madison, WI) in conjunction with
LUNAR software version 4.7e were used. Cross-calibration
analysis had been undertaken and no differences between
these 2 densitometers were reported [28].
Blood analyses
For both the CASA and VC cohorts, a venous sample
was obtained from each participant after an overnight
fast. Both cohorts were asked to refrain from smoking,
consuming alcohol or vigorous exercise in the 24 hours
before the clinic appointment. Last regular medications
were taken the day before and the morning dose was
held until after venous sampling. For CASA, the blood
was placed in ethylenediaminetetraacetic acid (EDTA)
tubes and transported immediately to the Institute for
Medical and Veterinary Sciences Laboratories (IMVS) in
South Australia for analysis. The blood was centrifuged
at 5000 rpm for 7 minutes and analyzed immediately at
37°C. For the VC, samples that had been centrifuged and
stored at −70°C were transferred to be processed by the
IMVS using the same methodology. The measured co-
efficients of variation (CV) were: alanine transferase
(ALT, 1.98%), aspartate transaminase (AST, 2.8%),albumin
(2.8%), creatinine (3%), lactate dehydrogenase (LDH,
2.2%), creatinine kinase (CK, 2.2%) and high sensitivity
C-reactive protein (hsCRP, 1.4%). A Beckman Coulter AU
2700 was used to perform the blood analysis and the
methods, reagents and calibration were as per manufac-
turer instructions.
Statistical analysis
Demographic characteristics in both groups were
expressed as mean ± standard deviation (SD). Independ-
ent samples t test was used to compare means between
the two cohorts. Differences between methods of LBM
measurements in the same cohort were examined by
paired t test. PEs for LBM were developed from CASA
where the independent variable was DXA derived LBM.
The initial 10 independent variables were gender, age,
weight, height, body mass index, albumin, AST, LDH,
CK and hsCRP. The best PEs (as assessed by adjusted
R2: the proportion of the variance of the dependent vari-
able accounted for by the independent variables, and ad-
justed for the number of independent variables) were
developed considering up to 6 equations with n predictors.
9:94 if maleð Þ SEE ¼ 3:61;R2 ¼ 90:7
leÞ þ 0:01 CKð Þ SEE ¼ 3:56;R2 ¼ 91:0
leÞ−0:56 CRPð Þ þ 0:01 CKð Þ SEE ¼ 3:47;R2 ¼ 91:4
leÞ þ 0:02 CKð Þ−0:58 CRPð Þ−0:02 LDHð Þ SEE ¼ 3:38;R2 ¼ 91:9
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ing the adjusted R2 value and likely clinical utility. In the
VC, LBM was calculated from the developed prediction
equations (LBMPE) and compared with DXA derived LBM
(LBMDXA).
The anthropometric PE was also compared to other
known PEs [12,15,16] in the NWAHS and FAMAS cohorts.
To assess the accuracy and predictive performance of
the prediction equations against LBMDXA, a regression
analysis as proposed by Lin [29] was undertaken and the
concordance correlation coefficient (ρc) was derived. ρc
measures how much the data deviates from the line of
identity representing congruence between the methods.
It is a product of Pearson correlation (ρ) and bias cor-
rection factor (Cb): ρc = ρ Cb [30].
In addition, to assess the level of agreement between
the two methods, Bland-Altman analysis was performed
to obtain the 95% limits of agreement [31]. Furthermore,
the goodness of fit with root mean square error (RMSE)
and bias (mean error [ME]) was also determined. RMSE
and ME were calculated according to the method of
Sheiner and Beal [32]. When the 95% confidence interval
of the ME includes 0 (i.e. no error), it indicates that
the model is not biased. In this study, mean differ-
ence was taken to be the same as ME. This gives an
estimation of R2 and the standard error of the esti-
mate [SEE]. SPSS 11.5 for Windows software (SPSS,
Inc., Chicago, IL) and the R statistical language (R
Foundation for Statistical Computing, Vienna, Austria)
were used for the analyses. P < 0.05 was considered
statistically significant.
Results
The CASA and VC cohorts were similar in age (CASA
mean [SD] 49.2 [17.0] vs. VC 50.6 [15.7] years), but
younger than the NWAHS (64.7 [9.84] years) and
FAMAS (62.3 [8.2] years) cohorts. The BMI (23.7 [2.3]
vs. 26.7 [5.2] kg/m2) and CK (93.3 [54.7] vs. 114.3 [66.0]
U/L), were significantly lower in the VC compared to
the CASA. LDH (194.4 [37.8] vs. 175.0 [37.4] U/L) and
albumin (40.4 [2.5] vs. 39.1 [3.1] g/L) were significantly
higher in the VC compared to the CASA. No significant
differences between the two cohorts were noted for
hsCRP or LBM. The BMI of subjects in the NWAHS
and FAMAS studies were higher at 28.2 [4.8] and 28.6
[4.6] kg/m2 respectively.
Based on adjusted R2 and potential clinical utility, the fol-
lowing PEs were selected for further validation in the VC:
LBMPE1 ¼ 22:93þ 0:68 weightð Þ−1:14 BMIð Þ−0:01 ageð Þ þ
LBMPE2 ¼ 22:06þ 0:67 weightð Þ−1:11 BMIð Þ þ 9:76 if mað
LBMPE3 ¼ 21:19þ 0:67 weightð Þ−1:04 BMIð Þ þ 9:51 if mað
LBMPE4 ¼ 23:17þ 0:64 weightð Þ−0:91 BMIð Þ þ 9:45 if maðTable 1 compares LBMPE1-4 to LBMDXA in the VC.
LBM predicted by all PEs was highly correlated with
LBMDXA. Concordance correlations, a measure of the
degree to which the data lie on the line of identity, were
all around 0.9 and similar to the Pearsons correlation co-
efficient. All PEs over-estimated LBMDXA, ranging from
1.9% for PE1to 4.1% for PE4. The limits of agreement
were similar for all PEs, approximately ± 15%. With in-
creasing number of variables, there were reducing RMSE
and mean error indicating improving precision and re-
ducing bias. Because of the costs involved with blood
investigations and the marginal benefits, only the an-
thropometric PE1was selected for further comparison
in the combined NWAHS and FAMAS cohorts (Tables 2,
3 and 4). Furthermore, biochemistry was not readily avail-
able from those cohorts.
Table 2 compares the performance of various PEs in-
cluding PE1 against LBMDXA in the total combined
NWAHS and FAMAS cohorts as well as in the two
gender groups, men and women. All PEs over-estimated
the LBMDXA in the total group. PE1 demonstrated a lower
mean error and RMSE score than the Heitmann and
Janmahasatian equations in the total population, men and
women cohorts. The Deurenberg equation performed the
best in the total population with the lowest mean error
and RMSE. However, when reviewed within gender
groups, PE1 performed better than the Deurenberg equa-
tion in women where both equations over-estimated
LBM. In men, the Deurenberg equation under-estimated
LBM whilst all other equations over-estimated LBM.
Table 3 compares the performance of the various PEs
across age groups (60–64, 65–79, ≥80). PE1 consistently
over-estimated LBMDXA across the age groups but
performed better (lowest ME, RMSE values and higher con-
cordance correlation coefficient) than the Janmahasatian
and Heitmann equations. The Deurenberg equation did not
perform as well as PE1 in the 50- < 65 years age group and
the ≥ 80 years age group and over-estimated LBM in the
50- < 65 years age group but under-estimated LBM in the
other two age groups.
Table 4 compares the performance of the various PEs
across various BMI groups. Once again, PE1 has the
smallest ME and RMSE compared with the Janmahasatian
and Heitmann equations across all the BMI groups ana-
lyzed but all of these consistently over-estimated LBMDXA
across the various BMI groups. PE1, in comparison with
the Deurenberg equation has a lower ME and RMSE
in the obese BMI (>30 kg/m2) and underweight BMI
Table 1 Validation of PE LBM in healthy adults from the Cytokine, Adiposity, Sarcopenia and Ageing (CASA) study
cohort (n = 195) against DXA derived LBM in the validation cohort (n = 52)








Total (n = 52)
LBMDXA 46.2 (9.49)
LBMPE1 48.1 (8.93) 1.88 ( 0.79, 2.97) 0.001 0.911* 0.891 (0.820, 0.935) [0.977] −9.72, 5.96 (−20.7 to 12.6%) 4.32 (2.84, 5.80)
LBMPE2 47.9 (8.95) 1.69 (0.62, 2.75) 0.003 0.915* 0.899 (0.832, 0.940) [0.982] −9.20, 5.83 (−19.9 to 12.6%) 4.15 (2.70, 5.60)
LBMPE3 47.7 (9.13) 1.50 (0.44 ,2.57) 0.006 0.917* 0.904 (0.840, 0.943) [0.986] −8.99, 5.98 (−19.5 to 13.0%) 4.07 (2.63, 5.51)
LBMPE4 47.1 (8.96) 0.86 (−0.22, 1.94) 0.114 0.914* 0.908 (0.846, 0.946) [0.994] −8.44, 6.72 (−18.3 to 14.6%) 3.93 (2.51, 5.35)
*P-value <0.001, R = correlation, SD = Standard Deviation.
RMSE = root mean squared prediction error, CI = confidence interval, R = Pearson Correlation Coefficient, Cb = Bias Correction Factor, ρc = Concordance
Correlation Coefficient.
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equation has less bias and better precision than PE1
in predicting LBMDXA in the 22-27 kg/m
2 BMI group.
The Deurenberg equation overestimated LBMDXA ex-
cept in the underweight and obese categories.
Discussion
In this study, prediction equations for LBM were devel-
oped and validated. It was hypothesized that the addition
of biochemistry variables would result in an improve-
ment in the performance of the PEs and this was seen.Table 2 Performance of the CASA (LBMPE1) and previously pu
and FAMAS cohorts (age 50 years and over) in the combined




Total (n = 2287)
LBMDXA 50.62 (10.8)
Heitmann equation 54.30 (10.7) 3.68 (3.53, 3.83) <0.001
Janmahasatian equation 54.23 (11.0) 3.61 (3.46, 3.76) <0.001
Deurenberg equation 50.64 (10.1) 0.02 (−0.14, 0.19) 0.777
LBMPE1 51.36 (10.6) 0.74 (0.59, 0.89) <0.001
Men (n = 1436)
LBMDXA 57.09 (7.50)
Heitmann equation 60.56 (7.80) 3.46 (3.25. 3.67) <0.001
Janmahasatian equation 61.18 (6.80) 4.09 (3.89, 4.29) <0.001
Deurenberg equation 56.76 (6.80) - 0.34 (−0.55, -0.12) 0.002
LBMPE1 58.22 (6.11) 1.12 (0.92, 1.33) <0.001
Women (n = 851)
LBMDXA 39.70 (5.30)
Heitmann equation 43.74 (5.55) 4.04 (3.83, 4.26) <0.001
Janmahasatian equation 42.50 (5.39) 2.81 (2.60, 3.01) <0.001
Deurenberg equation 40.32 (4.90) 0.63 (0.39, 0.87) <0.001
LBMPE1 39.78 (5.11) 0.08 (−0.12, 0.28) 0.433
Mean Error = DXA-PE; LBM, Lean Body Mass; DXA, Dual X-ray absorptiometry; RMSE
R, Pearson Correlation; Cb = Bias Correction Factor; ρc = Concordance Correlation CoHowever, the improvement was marginal and insuffi-
cient to justify the additional costs.
A significant finding from this study wasthe develop-
ment of a new anthropometric PE (PE1) for LBM: LBM=
22.932326 + 0.684668 (weight) -1.137156 (BMI) -0.009213
(age) + 9.940015 (if male). The close approximation to
LBMDXA generated by this equation was reflected by its
small bias (ME = 0.74 kg) and precision (RMSE = 3.73 kg).
It overestimated LBMDXA across gender, age and BMI
groups. This PE may be useful in care settings where
access to DXA may be limited, providing clinicians ablished FFM prediction equations in the NWAHS
cohort and by gender
or
or




0.940* 0.888 (0.880, 0.896) [0.945] −3.77, 11.1 5.24 (4.97, 5.51)
0.943* 0.884 (0.884, 0.899) [0.946] −3.78, 11.0 5.17 (4.90, 5.44)
0.931* 0.928 (0.923, 0.934) [0.998] −7.89, 7.93 3.95 (3.70, 4.20)
0.942* 0.939 (0.934, 0.944) [0.998] −6.58, 8.06 3.73 (2.48, 4.98)
0.863* 0.782 (0.764, 0.800) [0.906] −11.5, 4.57 5.30 (4.93, 5.67)
0.852* 0.728 (0.707, 0.747) [0.853] −12.0, 3.82 5.69 (5.32, 6.06)
0.838* 0.834 (0.818, 0.848) [0.995] −7.92, 8.60 4.14 (3.85, 4.43)
0.851* 0.822 (0.806, 0.837) [0.851] −6.78, 9.02 4.11 (3.80, 4.42)
0.833* 0.651 (0.620, 0.680) [0.782] −10.3, 2.26 5.12 (4.75, 5.49)
0.837* 0.722 (0.693, 0.749) [0.872] −8.91, 3.29 4.14 (3.83, 4.45)
0.759* 0.751 (0.721, 0.779) [0.990] −7.75, 6.49 3.61 (3.29, 3.93)
0.835* 0.835 (0.813, 0.854) [0.999] −5.91, 6.07 2.99 (2.74, 3.24)
, Root Mean Square Error; CI, Confidence interval; SD, Standard Deviation;
efficient; *p-value <0.001.
Table 3 Performance of the CASA (LBMPE1) and previously published FFM prediction equations in the NWAHS
and FAMAS cohorts (age 50 years and over) across various age groupings









years (n = 1265)
LBMDXA 52.27 (11.2)
Heitmann equation 56.47 (10.8) 4.20 (3.99, 4.40) <0.001 0.944* 0.879 (0.868, 0.890) [0.932] −11.6, 3.23 5.60 (5.26, 5.95)
Janmahasatian equation 55.62 (11.2) 3.35 (3.15, 3.55) <0.001 0.948* 0.907 (0.897, 0.915) [0.956] −10.6, 3.85 4.92 (4.61, 5.23)
Deurenberg equation 53.15 (10.0) 0.87 (0.66, 1.09) <0.001 0.938* 0.929 (0.921, 0.936) [0.990] −8.72, 6.98 4.02 (3.73, 4.31)
LBMPE1 52.77 (10.7) 0.50 (0.30, 0.70) <0.001 0.948* 0.946 (0.939, 0.951) [0.998] −6.68, 7.68 3.62 (3.36, 3.88)
Age 65–79, years (n = 882)
LBMDXA 49.09 (9.91)
Heitmann equation 52.23 (10.0) 3.14 (2.90, 3.38) <0.001 0.933* 0.887 (0.873, 0.899) [0.951] −10.5, 4.18 4.82 (4.35, 5.29)
Janmahasatian equation 53.03 (10.5) 3.93 (3.69, 4.18) <0.001 0.933* 0.862 (0.846, 0.876) [0.925] −11.5, 3.66 5.46 (4.97, 5.95)
Deurenberg equation 48.19 (9.14) −0.90 (−1.15, -0.65) <0.001 0.924* 0.916 (0.905, 0.926) [0.993] −6.70, 8.50 3.90 (3.45, 4.35)
LBMPE1 50.20 (10.2) 0.98 (0.73, 1.22) <0.001 0.929* 0.925 (0.915, 0.934) [0.995] −6.57, 8.53 3.90 (3.48, 4.32)
Age ≥80, years (n = 140)
LBMDXA 44.48 (8.64)
Heitmann equation 46.71 (9.20) 2.23 (1.60, 2.85) <0.001 0.929* 0.902 (0.868, 0.928) [0.969] −9.05, 4.59 4.06 (3.20, 4.92)
Janmahasatian equation 48.46 (10.1) 3.97 (3.29, 4.66) <0.001 0.936* 0.850 (0.806, 0.883) [0.906] −11.4, 3.46 5.43 (4.31, 6.55)
Deurenberg equation 42.46 (8.41) −2.03 (−2.58, -1.48) <0.001 0.937* 0.911 (0.880, 0.934) [0.971] −3.97, 8.03 3.61 (2.85, 4.37)
LBMPE1 45.84 (9.81) 1.36 (0.80, 1.93) <0.001 0.941* 0.923 (0.897, 0.943) [0.981] −5.39, 8.11 3.63 (2.90, 4.36)
Mean Error = DXA-PE; LBM, Lean Body Mass; DXA, Dual X-ray absorptiometry; RMSE, Root Mean Square Error; CI, Confidence interval; SD, Standard Deviation;
R, Pearson Correlation; Cb = Bias Correction Factor; ρc = Concordance Correlation Coefficient; *p-value <0.001.
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http://www.biomedcentral.com/2050-6511/14/53practical alternative to assess LBM. Furthermore, it also
provides a bedside option in hospitals for ill and frail pa-
tients where transport for DXA assessment may be diffi-
cult. Whilst BIA may be simple technique to be used
at the beside, BIA may be affected by clinical factors
such as ascites, hydration status, food intake and ex-
ercise and cannot be used in older people with pace-
makers [11]. Skin fold measurements may be a cheaper
option but the accuracy is operator dependent and the
loss of subcutaneous tissue in older people may also affect
accuracy [33].
Interestingly, the Deurenberg equation appeared to
have less bias with a ME of 0.02 kg but similar precision
with a RMSE of 3.95 when compared to the newly devel-
oped PE. However, across gender, age and BMI groups,
it at times over-estimated and at other times under-
estimated the LBMDXA [14]. The newly developed PE1
appeared to have better precision (smaller RMSE) and
less bias (lower ME) than the Deurenberg equation only
in women and in obese older individuals. In clinical
settings where the dose normalization to LBM is re-
quired, an overestimation of LBM could potentially
lead to higher incidence of dose limiting toxicity.
Sarcopenia was an important predictor of toxicity in
women with metastatic cancer and colon cancer receivingchemotherapy [4,6]. It was suggested that chemotherapy
dose normalization to LBM may reduce the excess toxicity
in women. PE1 in our study potentially offers a more ac-
curate estimation of LBM over Deurenberg equation in
women and obese individuals and may have clinical utility
in this two patient population groups.
This study had several limitations. Only 6% of the
study population was under-weight with a BMI < 22 kg/m2
and therefore, it remains important to validate this newly
developed PE in an under-weight population where
sarcopenia is likely to be common. Furthermore, only
Caucasians were studied and therefore generalizing these
results to other ethnic communities is not possible and
ethnic specific PEs will need to be developed. Different
DXA machines were used in the CASA and VC cohort
studies. This may have affected the results as even in the
same person, reported measurements of the same tissue
mass can be different with different DXA machines [34].
The researchers adjusted for the difference between the
machines in the validation aspects of this study but clearly,
it would have been preferable to use the same DXA ma-
chine in both cohorts. The use of other anthropometry
measurements such as calf or arm circumference may im-
prove the performance of prediction equations and needs
to be explored in future studies.
Table 4 Performance of the CASA (LBMPE1) and previously published FFM prediction equations in the NWAHS
and FAMAS cohorts (age 50 years and over) across various body mass index groupings




R ρc (95% CI) [Cb] 95% limits of
agreement
RMSE (95% CI), kg
BMI < 22 kg/m2
(n = 135)
LBMDXA 42.45 (8.85)
Heitmann equation 44.85 (7.65) 2.40 (1.85, 2.96) <0.001 0.932* 0.885 (0.847, 0.914) [0.949] −4.12, 8.92 4.04 (3.21, 4.87)
Janmahasatian
equation
43.72 (9.26) 1.27 (0.77, 1.77) <0.001 0.946* 0.937 (0.914, 0.955) [0.989] −4.65, 7.19 3.21 (2.55, 3.87)
Deurenberg equation 41.26 (8.04) −1.18 (−1.77, -0.60) <0.001 0.921* 0.909 (0.876, 0.933) [0.986] −8.04, 5.68 3.62 (2.86, 4.36)
LBMPE1 43.52 (9.04) 1.08 (0.57, 1.59) <0.001 0.944* 0.937 (0.913, 0.955) [0.993] −4.92, 7.08 3.18 (2.53, 3.83)
BMI 22- < 27 kg/m2
(n = 847)
LBMDXA 47.45 (9.18)
Heitmann equation 50.67 (8.67) 3.22 (2.99, 3.44) <0.001 0.933* 0.874 (0.860, 0.888) [0.938] −3.42, 9.86 4.62 (4.26,4.98)
Janmahasatian
equation
50.81 (9.71) 3.36 (3.13, 3.59) <0.001 0.937* 0.880 (0.866, 0.893) [0.939] −3.41, 10.1 4.77 (4.39, 5.15)
Deurenberg equation 47.91 (8.68) 0.45 (0.22, 0.68) 0.001 0.928* 0.925 (0.915, 0.934) [0.997] −6.42, 7.32 3.46 (3.16, 3.76)
LBMPE1 48.64 (9.45) 1.19 (0.96, 1.41) <0.001 0.938* 0.930 (0.920, 0.938) [0.992] −5.41, 7.79 3.51 (3.20, 3.82)
BMI 27- < 30 kg/m2
(n = 596)
LBMDXA 52.00 (9.83)
Heitmann equation 55.65 (9.48) 3.65 (3.36, 3.95) <0.001 0.929* 0.867 (0.847, 0.883) [0.933] −3.65, 10.9 5.16 (4.69, 5.63)
Janmahasatian
equation
56.11 (9.75) 4.12 (3.83, 4.41) <0.001 0.932* 0.857 (0.837, 0.874) [0.919] −3.08, 11.3 5.47 (4.97, 5.97)
Deurenberg equation 52.58 (9.23) 0.59 (0.30, 0.88) <0.001 0.928* 0.925 (0.912, 0.935) [0.996] −6.72, 7.90 3.70 (3.35, 4.05)




Heitmann equation 59.30 (11.7) 4.50 (4.19, 4.80) <0.001 0.937* 0.867 (0.847, 0.883) [0.933] −3.80, 12.8 6.12 (5.53, 6.71)
Janmahasatian
equation
58.93 (11.0) 4.13 (3.83, 4.43) <0.001 0.937* 0.857 (0.837, 0.974) [0.919] −4.02, 12.3 5.80 (5.22, 6.38)
Deurenberg equation 54.07 (10.6) −0.74 (−1.08, -0.39) <0.001 0.917* 0.925 (0.912, 0.935) [0.996] −10.0, 8.55 4.70 (4.14, 5.26)
LBMPE1 54.88 (11.3) 0.08 (−0.23, 0.38) 0.628 0.936* 0.929 (0.918, 0.939) [0.997] −8.15, 8.31 4.11 (3.61, 4.61)
Mean Error = DXA-PE; LBM, Lean Body Mass; DXA, Dual X-ray absorptiometry; RMSE, Root Mean Square Error; CI, Confidence interval; SD, Standard Deviation;
R, Pearson Correlation; Cb = Bias Correction Factor; ρc = Concordance Correlation Coefficient.
*p-value <0.001.
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This study describes the development of a new predic-
tion equation for LBM as estimated by DXA. This new
PE consistently over-estimates across gender, age and
BMI groups. There remains a need to confirm these
findings in older and leaner cohorts, cohorts with diseases
(e.g. renal failure), as well as other cohorts with varying
ethnicity. The anthropometric PE is an alternative when
access to DXA is difficult and this might occur with home
bound frail older people as well as people residing in rural
areas. The availability of simple and accuratemethods to
estimate LBM might be the necessary catalyst required tosupport better prescribing to limit toxicity in the oncology
setting.
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